Shareholder Alert: Ademi LLP investigates whether Chembio Diagnostics, Inc. has obtained a Fair Price in its transaction with Biosynex

Provided By PR Newswire

Last update: Apr 20, 2023

MILWAUKEE, April 20, 2023 /PRNewswire/ -- Ademi LLP is investigating Chembio (NASDAQ: CEMI) for possible breaches of fiduciary duty and other violations of law in its transaction with Biosynex.